key: cord-0703987-6twypq0p authors: SO, Ho; MAK, Joyce Wing-Yan; SO, Jacqueline; LUI, Grace; LUN, Frankie; LEE, Jolly; CHAN, Shirley; HO, Carmen; CHAN, Jacky Man-Chun; KONG, Shing-Pak; NG, Woon-Leung; TAM, Lai-Shan title: Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: a population-based study date: 2020-07-24 journal: Semin Arthritis Rheum DOI: 10.1016/j.semarthrit.2020.07.012 sha: 997725a6444655f4ed4c6105ceb1caf87bb2012d doc_id: 703987 cord_uid: 6twypq0p OBJECTIVES: Patients with rheumatologic diseases might be more susceptible to COVID-19 and carry a poorer prognosis. The aim of this study is to examine the incidence and outcomes of all COVID-19 patients with rheumatologic conditions in Hong Kong. METHODS: This is a population-based retrospective study. All patients tested positive for SARS-CoV-2 by PCR with a previous diagnosis of rheumatologic diseases were reviewed. The incidence of COVID-19 in patients with rheumatologic conditions was calculated and compared to the general population in Hong Kong. Descriptive data of those rheumatologic patients with COVID-19 and the clinical course of the index infection were presented. RESULTS: Up till 27 May 2020, there were 1067 cases of COVID-19 diagnosed in Hong Kong which had a population of 7.5 million. Out of the 39,835 patients with underlying rheumatologic diseases, we identified 5 PCR confirmed COVID-19 cases. The estimated incidence of COVID-19 was 1.26 cases per 100,000 patients with rheumatologic diseases, compared to 1.42 per 100,000 in the general population. All 5 patients had inflammatory arthropathies. One patient was on hydroxychloroquine and sulphasalazine, and one was on methotrexate. None of the 3534 patients on b/tsDMARDs was infected. Four patients had leucopenia/lymphopenia and stool viral PCR was positive in 3 patients. All patients made uneventful recovery without complications or flare of underlying diseases. CONCLUSIONS: We found no alarming signals of increased frequency or severity of COVID-19 in patients with rheumatologic diseases, although extrapolation of the results to other populations with different infection control strategies should be made with caution. On 12 th March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) a pandemic [1] . Patients with rheumatologic diseases are at increased risk of infection due to the underlying systemic inflammation and the use of immunosuppressive therapies [2] . They might be more likely to contract the virus. The increased prevalence of comorbidities, such as cardiovascular and pulmonary diseases, in rheumatologic patients have also been reported to be the poor prognostic factors of COVID-19 [3, 4] . In contrast, rheumatologic patients might be unexpectedly protected, by virtue of the medications that are using. Much attention has been paid to the controversial anti-SARS-CoV-2 effect of hydroxychloroquine [5] . The other immunemodulators used in our patients may counteract the overwhelming pro-inflammatory cytokines release in the cytokine storm associated with COVID-19 [6] . On the other hand, rheumatologic diseases might be affected by the autoimmunity triggers due to the SARS-CoV-2 [7] . At the present time, there are mainly self-reported survey or registry data. Large scale population-based studies are lacking. It remains uncertain how rheumatologic diseases or medications will affect the susceptibility and disease course of COVID-19, as well as how SARS-CoV-2 impacts patients with rheumatologic conditions. We aimed to study the incidence, baseline characteristics, disease course and outcomes of COVID-19 patients with rheumatologic diseases in Hong Kong. This is a territory-wide multi-centered retrospective observational study. An extensive surveillance scheme was implemented in Hong Kong early in the outbreak. All patients presented to the hospitals with fever, respiratory symptoms or chest x-ray pneumonic changes were tested for SARS-CoV-2 by polymerase chain reaction (PCR) via nasapharyngeal aspiration (NPA). Patients with fever or respiratory symptoms seen in the clinics were also encouraged to undergo the test. Asymptomatic inbound travelers from high risk areas were also tested. All patients tested positive were admitted to the hospitals for further management. The treatments the patients received were at the discretion of the treating physicians. Patient identification was done using the Clinical Data Analysis and Reporting System (CDARS), which was constructed for recordkeeping and research purposes in Hong Kong [8] . It recorded and centralized information on patient demographics, laboratory results, diagnoses, and dates of hospital admissions and discharges. Data validation in CDARS demonstrated a high coding accuracy and the system has been extensively used in large-scale epidemiological studies [9] [10] [11] [12] . Due to the small number of cases, only descriptive data were presented. The incidence of rheumatologic patients with COVID-19 in the Hong Kong population was calculated. The incidence of the COVID-19 infection in rheumatologic patients was deduced using a crude estimation of the number of patients with rheumatologic conditions in Hong Kong. It was numerically compared with the overall Hong Kong incidence of COVID-19 infection. Only methotrexate was stopped due to the infection after hospitalization. All of them presented with respiratory symptoms, and two had diarrhea and vomiting. Besides NPA, 2 patients with diarrhea and 1 without were tested positive for stool viral PCR. Four out of 5 patients had leucopenia and lymphopenia. They mostly had mild COVID-19 disease without developing any significant complication. Only one patient required supplementary oxygen therapy temporarily. Remdesivir was given in 2 patients including the one requiring oxygen therapy. Lopinavir/ritonavir in combination with interferon beta were given in another patient. Their symptoms resolved in 7 to 14 days and viral clearance was documented in 19 to 31 days. There was no obvious flare of the underlying rheumatologic diseases before discharge from the hospital which was no later than the date of viral clearance. In this territory-wide population-based study, we found an apparently low incidence of laboratory proven COVID-19 in patients with rheumatologic disease in Hong Kong, which was similar to that of the general public. Monti and colleagues provided an early account of patients with arthritis in Lombardy, Italy, one of the most heavily hit regions [13] . Out of the 320 surveyed patients, 4 (1.25%) were diagnosed of COVID-19 infection. In a study conducted in Milan, out of 530 patients on b/tsDMARDs, 3 (0.57%) were diagnosed to have COVID-19 by PCR [14] . In another Italian cohort from a different region, only 2 (0.21%) of the 916 patients with rheumatologic diseases were virologically diagnosed to have COVID-19 and the incidence was not significantly different from the general population [15] . A similar finding of comparable COVID-19 incidence rate between rheumatologic patients and the general population (0.48% and 0.58% respectively) was again reported in a Spanish study [16] . However, all of the above studies were conducted in the form of patient self-reported survey which might affect the validity of the results. Whether rheumatologic disease is a poor prognostic factor for COVID-19 is debatable. In our study, the disease courses of the 5 patients with COVID-19 were largely uneventful. A similarly reassuring message was conveyed from the above mentioned Italian cohorts. On the other hand, early data from the COVID-19 Global Rheumatology Alliance, the international initiative to collect data of rheumatologic patients with COVID-19, revealed an overall death rate of 5% in 110 cases [17] . In a French report of 17 systemic lupus erythematosus patients with COVID-19, 5 patients required invasive mechanical ventilation and 2 patients died [18] . In the latest report from the Global Rheumatology Alliance, corticosteroids use was found to be the poor prognostic factor, and patients on anti-TNFs had a decreased odds of hospitalization [19] . However, as these are survey or registry data, they are subject to selection or reporting bias. Leucopenia and gastro-intestinal (GI) symptoms were common in our patients and might be a unique finding. A systemic review showed a high frequency of lymphopenia but not leucopenia in patients with COVID-19 [20] . Lymphocytes, the major antiviral cells, were found to be prone to decrease continually in patients with severe COVID-19 [21] . At the same time, as the illness progressed, neutrophilia emerged and was an indicator of poor prognosis [22] . This might explain the relatively low total leucocyte counts in our patients with benign disease courses. On the other hand, another review suggested that 12% of patients with COVID-19 would manifest GI symptoms, although viral shedding was observed in 40.5% of patients [23] . The diagnostic, prognostic and infection control implications of these findings need to be further studied. Anti-endemic measures, including border restrictions, quarantine, and social distancing were implemented early to curb the spread of the infection in Hong Kong [24] . All these, but without complete society lock-down, together with a 96.6% compliance of mask usage of the general public were believed to the reasons for the low overall incidence of COVID-19 in Hong Kong [25] . The potentially even more stringent behavioral measures adopted by our rheumatologic patients due to the awareness of an increased risk, may lead to underestimation of the true incidence. The different testing strategies applied could have equally affected the rate of COVID-19 diagnosis. The number of COVID-19 PCR tests performed in Hong Kong was 27,057 per million population, which was comparable to most of the developed countries [26, 27] . It is also possible that the COVID-19 infections presented to us are only the tip of the iceberg, as the many of cases are asymptomatic or minimally symptomatic. We extended the testing to asymptomatic inbound travelers. No asymptomatic COVID-19 patient with rheumatologic diseases was found. Unfortunately, wide-spread serological testing was not done which might provide a better picture of the epidemiology of the disease. Another major limitation of our study is the small sample size of the COVID-19 patients which hampered the inference of our results. To conclude, our findings could provide further reassurance about the incidence and possibly outcome of COVID-19 in patients with rheumatologic diseases. Nevertheless, these should be interpreted in the context of all the mitigation measures implemented in Hong Kong, and may not be applicable to other parts of the world adopting different strategies. The results also support avoidance of interrupting immunosuppressive therapies, at least before COVID-19 is diagnosed. The implications of the apparent high frequency of leucopenia and positive stool viral PCR require further investigations. World Health Organization. Coronavirus disease (COVID-19) outbreak Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study Temporal relationships between systemic lupus erythematosus and comorbidities Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The perspectives of clinical immunologists from China Infections: A double-edge sword in autoimmunity Introduction: caring for our community's health Validity of major osteoporotic fracture diagnosis codes in the Clinical Data Analysis and Reporting System in Hong Kong Influenza-related hospitalizations among children in Hong Kong Association between dabigatranvs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies What is the true incidence of COVID-19 in patients with rheumatic diseases? SARS-CoV-2 Infection in Patients With Autoimmune Rheumatic Diseases in Northeast Italy: A Cross-Sectional Study on 916 Patients Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry Hematological findings in coronavirus disease 2019: indications of progression of disease Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan Hematologic parameters in patients with COVID-19 infection Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: a systematic review and meta-analysis Impact assessment of nonpharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study The role of community-wide wearing of face mask for control of coronavirus disease 2019 (COVID-19) epidemic due to SARS-CoV-2 The Government of the Hong Kong Special Administrative Region. Statistics on Testing for COVID-19 in Hong Kong Rate of COVID-19 testing in most impacted countries worldwide as of Contributors All authors have substantially contributed to all aspects of this study Patient consent for publication Not required.Data availability statement Data can be shared upon request. Data availability statement Data can be shared upon request. and LT: study design, data analysis and interpretation, drafting the manuscript. JS, FL, JL, SC, CH, JMC, SK and WN: data acquisition. All authors critically revised and approved the final version of the manuscript.Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Case with rheumatologic diseases